<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-17</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-17</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>38</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
GSE318408/GSE318867/GSE318663æ­ç¤ºè¡€ç®¡STINGæ¿€æ´»ä¿ƒè¿›å°ç»†èƒè‚ºç™Œï¼ˆSCLCï¼‰NKç»†èƒæŠ—è‚¿ç˜¤å…ç–«ï¼Œä¸ºSCLCå…ç–«æ²»ç–—æä¾›æ–°é¶ç‚¹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«ä¸å¾®ç¯å¢ƒè°ƒæ§ï¼ˆSCLCã€åµå·¢ç™Œã€å‰åˆ—è…ºç™Œã€è‚ºç™Œï¼‰<br />
- ç¥ç»ç³»ç»Ÿå‘è‚²ä¸ç–¾ç—…ï¼ˆé˜¿å°”èŒ¨æµ·é»˜ç—…ã€è„‘å‘è‚²ï¼‰<br />
- ç»†èƒä»£è°¢ä¸ç‚ç—‡ï¼ˆæ–°ç”Ÿå„¿è´¥è¡€ç—‡ï¼‰</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆå•ç»†èƒRNA-seqä¸ATAC-seqï¼ˆGSE309579ï¼‰å®ç°å¯¹è‚¿ç˜¤åŸºå› è°ƒæ§åŠ¨åŠ›å­¦çš„ç²¾ç»†è§£æã€‚<br />
- ç©ºé—´è½¬å½•ç»„å­¦ï¼ˆGSE318867ï¼‰ç»“åˆåŸºå› ç»„å­¦åˆ†æï¼Œæ­ç¤ºè‚¿ç˜¤å¾®ç¯å¢ƒä¸­ç»†èƒé—´çš„ç›¸äº’ä½œç”¨ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
AIæ­ç¤ºé˜¿å°”èŒ¨æµ·é»˜ç—…åŸºå› è°ƒæ§æ–°æœºåˆ¶ï¼Œå‘ç°èƒ½åŠ é€ŸDNAé‡ç»„çš„é…¶N4BP2æ˜¯å¤šç§ç™Œç—‡çš„å…³é”®é©±åŠ¨å› ç´ ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼šåˆ©ç”¨AIç»˜åˆ¶å¤§è„‘åŸºå› è°ƒæ§å›¾è°±ï¼Œç†è§£ç–¾ç—…å‘ç”Ÿæœºåˆ¶ã€‚<br />
- èƒ°è…ºç™Œï¼šæ­ç¤ºç¥ç»ç³»ç»Ÿä¸èƒ°è…ºç™Œç»†èƒçš„ååŒä½œç”¨ï¼ŒåŠ é€Ÿæ—©æœŸç™Œç—‡è¿›ç¨‹ã€‚<br />
- ç™Œç—‡DNAé‡ç»„ï¼šå‘ç°N4BP2é…¶æ˜¯å¯¼è‡´æŸ“è‰²ä½“ç²‰ç¢æ€§é‡æ’ï¼ˆchromothripsisï¼‰çš„å…³é”®ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- SIGNETï¼šæ–°å‹AIç³»ç»Ÿï¼Œç”¨äºç»˜åˆ¶é˜¿å°”èŒ¨æµ·é»˜ç—…å¤§è„‘çš„åŸºå› è°ƒæ§ç½‘ç»œã€‚<br />
- æŸ“è‰²ä½“ç²‰ç¢æ€§é‡æ’ï¼ˆChromothripsisï¼‰æœºåˆ¶ï¼šé¦–æ¬¡å‘ç°N4BP2é…¶åœ¨å…¶ä¸­æ‰®æ¼”çš„è§’è‰²ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (34æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE318408 è¡€ç®¡ STING æ¿€æ´»ä¿ƒè¿›å°ç»†èƒè‚ºç™Œä¸­ NK ç»†èƒçš„æŠ—è‚¿ç˜¤å…ç–« [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunityã€NK cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Marco Campisi ; Tatsuya Osaki ; David A Barbie ; Navin R MahadevanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSmall cell lung cancer (SCLC) typically displays a "cold" tumor microenvironment with a paucity of immune infiltrate. Neuroendocrine SCLC cells also profoundly repress MHC-I expression, rendering them vulnerable to NK cell-mediated cytotoxicity. Here, we confirm that neuroendocrine SCLC cells are sensitive to NK cell mediated attack, yet quantitative spatial profiling of the SCLC immune microenvironment in patient samples reveals that effector immune cells, including NK cells, are excluded from MHC-Ilow/neg SCLC regions. To study this biology, we develop dynamic single cell RNA sequencing of microphysiological immune tumor environments (DynaMITE-seq) and integrate findings with spatial transcriptomics in patient tissue, unveiling the microvasculature as a major checkpoint restricting NK cell extravasation/recruitment. We demonstrate that activation of vascular Stimulator of Interferon Genes (STING) signaling restores NK cell infiltration and killing of neuroendocrine SCLC, suggesting a strategy to overcome this key SCLC immunologic barrier and prime therapeutic response to DLL3-targeted CAR-NK cell therapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318408" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE318867 è¡€ç®¡ STING æ¿€æ´»ä¿ƒè¿›å°ç»†èƒè‚ºç™Œä¸­ NK ç»†èƒçš„æŠ—è‚¿ç˜¤å…ç–« [ç©ºé—´è½¬å½•ç»„]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunityã€NK cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Marco Campisi ; Ian Dryg ; Jason Weirather ; David A Barbie ; Navin R MahadevanSeries Type : OtherOrganism : Homo sapiensSmall cell lung cancer (SCLC) typically displays a "cold" tumor microenvironment with a paucity of immune infiltrate. Neuroendocrine SCLC cells also profoundly repress MHC-I expression, rendering them vulnerable to NK cell-mediated cytotoxicity. Here, we confirm that neuroendocrine SCLC cells are sensitive to NK cell mediated attack, yet quantitative spatial profiling of the SCLC immune microenvironment in patient samples reveals that effector immune cells, including NK cells, are excluded from MHC-Ilow/neg SCLC regions. To study this biology, we develop dynamic single cell RNA sequencing of microphysiological immune tumor environments (DynaMITE-seq) and integrate findings with spatial transcriptomics in patient tissue, unveiling the microvasculature as a major checkpoint restricting NK cell extravasation/recruitment. We demonstrate that activation of vascular Stimulator of Interferon Genes (STING) signaling restores NK cell infiltration and killing of neuroendocrine SCLC, suggesting a strategy to overcome this key SCLC immunologic barrier and prime therapeutic response to DLL3-targeted CAR-NK cell therapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318867" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE318663 è¡€ç®¡STINGæ¿€æ´»ä¿ƒè¿›NKç»†èƒåœ¨å°ç»†èƒè‚ºç™Œä¸­çš„æŠ—è‚¿ç˜¤å…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunityã€NK cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318663" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE319188 é€šè¿‡ LHRH-NanoTi é¶å‘é€’é€ TGF-Î² æŠ‘åˆ¶å‰‚å¯é€†è½¬åµå·¢ç™Œä¸­ NAT10/ac4C ä»‹å¯¼çš„é¡ºé“‚è¯±å¯¼çš„å…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€tumor microenvironment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Fei LvSeries Type : OtherOrganism : Mus musculusBackground: Platinum-based chemotherapy for ovarian cancer is frequently compromised by the development of resistance, a process often accompanied by an immunosuppressive tumor microenvironment. The molecular mechanisms linking cisplatin resistance to immune evasion remain poorly understood, hindering the development of effective combination therapies.Results: This study reveals that cisplatin-induced immunosuppression and resistance are driven by a reduction in N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification, which produces two parts of unfavorable effects: 1) activating the DNA damage repair pathway, thereby confers resistance to cisplatin; 2) enhancing the expression of TGF-Î² via NAT10's interaction with ribosomal proteins RPS3 and RPS6. The elevated TGF-Î² increases the infiltration of myeloid-derived suppressor cells (MDSCs), M2 macrophages, exhausted CD8+ T cells, and regulatory T cells (Tregs) within the tumor microenvironment. To target this pathway, we developed a LHRH receptor-targeted nanodelivery system for a TGF-Î² inhibitor, which synergized with cisplatin to achieve superior antitumor efficacy by effectively reversing the immunosuppressive microenvironment.Conclusions: Our study defines the NAT10/ac4Câ€“TGF-Î² axis as a pivotal mechanism coordinating cisplatin resistance and immunosuppression in ovarian cancer. These findings propose targeted inhibition of TGF-Î² signaling as a promising therapeutic strategy to overcome platinum resistance by revitalizing the antitumor immune response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319188" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE318885 SMARCA4 é€šè¿‡ H3K27 ä¹™é…°åŒ–è°ƒèŠ‚ PROX1 ä¿ƒè¿›å‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œæ©æ‰å¢èƒºè€è¯æ€§ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chenwei Wu ; Mayao Luo ; Shidong Lv ; Qiang WeiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensEnzalutamide resistance is a dynamic process often culminating in the aggressive progression to neuroendocrine prostate cancer (NEPC). This lineage plasticity is hypothesized to be driven by underlying epigenetic alterations, yet the core molecular drivers remain unclear. Elucidating these factors is of significant clinical importance for overcoming resistance. To model this transition, we established a dynamic gradient-resistant cell model simulating the clinical response to enzalutamide, and found robust upregulation of the chromatin remodeling factor SMARCA4 in resistant cells. Both in vitro and in vivo experimental results demonstrated that inhibiting SMARCA4 effectively suppresses tumor progression and reverses neuroendocrine transformation. Mechanistically, integrated multi-omics analysis, correlation studies, and protein interaction experiments revealed the transcription factor PROX1 as a crucial downstream target of SMARCA4, where its inhibition alone was sufficient to reverse the aggressive malignancy and neuroendocrine characteristics of resistant cells. We further demonstrated that SMARCA4 enhances H3K27ac levels and chromatin accessibility at the PROX1 locus to regulate its expression. Importantly, the tumor-suppressive effect of SMARCA4 knockdown could be rescued by histone deacetylase inhibitors (HDACi), achieving a level of recovery comparable to PROX1 overexpression. In summary, this study defines a core epigenetic pathway, showing that increased SMARCA4 activity promotes luminal-to-neuroendocrine transformation by enhancing histone acetylation and chromatin accessibility at the PROX1 locus. Targeting the SMARCA4-PROX1 axis provides a valuable therapeutic strategy for combating enzalutamide resistance and NEPC progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318885" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE318884 SMARCA4 é€šè¿‡ H3K27 ä¹™é…°åŒ–è°ƒæ§ PROX1 ä¿ƒè¿›å‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œæ©æ‰å¢èƒºè€è¯æ€§ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chenwei Wu ; Mayao Luo ; Shidong Lv ; Qiang WeiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEnzalutamide resistance is a dynamic process often culminating in the aggressive progression to neuroendocrine prostate cancer (NEPC). This lineage plasticity is hypothesized to be driven by underlying epigenetic alterations, yet the core molecular drivers remain unclear. Elucidating these factors is of significant clinical importance for overcoming resistance. To model this transition, we established a dynamic gradient-resistant cell model simulating the clinical response to enzalutamide, and found robust upregulation of the chromatin remodeling factor SMARCA4 in resistant cells. Both in vitro and in vivo experimental results demonstrated that inhibiting SMARCA4 effectively suppresses tumor progression and reverses neuroendocrine transformation. Mechanistically, integrated multi-omics analysis, correlation studies, and protein interaction experiments revealed the transcription factor PROX1 as a crucial downstream target of SMARCA4, where its inhibition alone was sufficient to reverse the aggressive malignancy and neuroendocrine characteristics of resistant cells. We further demonstrated that SMARCA4 enhances H3K27ac levels and chromatin accessibility at the PROX1 locus to regulate its expression. Importantly, the tumor-suppressive effect of SMARCA4 knockdown could be rescued by histone deacetylase inhibitors (HDACi), achieving a level of recovery comparable to PROX1 overexpression. In summary, this study defines a core epigenetic pathway, showing that increased SMARCA4 activity promotes luminal-to-neuroendocrine transformation by enhancing histone acetylation and chromatin accessibility at the PROX1 locus. Targeting the SMARCA4-PROX1 axis provides a valuable therapeutic strategy for combating enzalutamide resistance and NEPC progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318884" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE319552 é…®ä½“å’Œç³–é…µè§£ä»£è°¢æ˜¯æ–°ç”Ÿå„¿è´¥è¡€ç—‡ç‚ç—‡çš„å…³é”®è°ƒèŠ‚å› å­</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammationã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : BjÃ¶rn Klabunde ; Ole BÃ¦k ; Duc Ninh NguyenSeries Type : Expression profiling by high throughput sequencingOrganism : Sus scrofaNeonatal sepsis is a life-threatening condition in preterm infants, primarily due to a dysregulated immunometabolic response to infection. Sepsis and infection mortality are associated with excessive glycolysis-induced inflammation, impaired mitochondrial oxidative phosphorylation (OXPHOS) and loss of disease tolerance. Reduced glucose intake can reverse these dysregulations, but it is unclear how the mechanistic control of glycolysis-OXPHOS balance drives defense strategies and infection outcomes. Here, in a preterm piglet model of neonatal sepsis, glycolysis inhibition with 2-deoxyglucose (2-DG) completely prevents acute infection mortality, reduces systemic inflammation and markers of liver injury, accompanied by enhanced mitochondrial metabolism and disease tolerance. Strikingly, this protection by 2-DG is conferred despite elevated blood glucose levels and higher bacterial burdens than the infected controls. Alternatively, partial replacement of glucose intake with the ketone beta-hydroxybutyrate (BHB) abolishes sepsis-related mortality via improving disease tolerance and clinical parameters.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319552" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE319314 å°èƒ¶è´¨ç»†èƒçº¿ç²’ä½“é€šè¿‡ä»£è°¢å’Œè½¬å½•é‡ç¼–ç¨‹æ”¯æŒäººç±»3Dä½“å¤–è„‘æ¨¡å‹ä¸­çš„ç¥ç»å…ƒæˆç†Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€Neuronal<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sydney P Sterben ; Charitha C Anamala ; Sahan B Kansakar ; Vaishnavi Koduri ; Volha LiaudanskayaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAutism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by disrupted neuronal circuit maturation. Emerging evidence implicates microglial function and mitochondrial regulation as contributors to ASD-associated biology, yet the mechanisms linking these processes to neuronal development remain poorly defined. Neuronal maturation requires tightly coordinated metabolic and transcriptional remodeling, in which mitochondria play a central role in regulating the developmental tempo and metabolic identity, while microglia modulate neuronal synaptic network maturation; however, whether microglia influence neuronal development through direct mitochondrial contributions remains unknown. Here, using a 3D human in vitro brain model, we show that microglial mitochondria can act as transferable cues that promote metabolic, mitochondria-dynamic, and transcriptional aspects of neuronal maturation. Neurons treated with microglial mitochondria exhibited enhanced oxidative metabolism, improved mitochondrial dynamics, and activation of gene programs associated with nervous system development and neurogenesis. These effects were accompanied by increased expression of dendritic maturation markers, supporting the view that transferred mitochondria can contribute to the regulation of neuronal state. However, full structural and synaptic maturation required the combined action of microglia-derived mitochondria and secreted signaling factors. Together, this study identified microglial mitochondrial transfer as a contributor to neuronal maturation with potential relevance to developmental trajectories disrupted in ASD.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319314" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE319246 ApoE4 é€šè¿‡ AsxL1/LXRÎ±â€“H3K4me3 è½´çš„è¡¨è§‚é—ä¼ é‡ç¼–ç¨‹é©±åŠ¨é˜¿å°”èŒ¨æµ·é»˜ç—…ä¸­çš„å°èƒ¶è´¨ç»†èƒè„‚è´¨å¤±è°ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground The Îµ 4 allele of apolipoprotein E gene (ApoE) stands as the greatest genetic risk factor for late-onset Alzheimerâ€™s disease (AD). Although microglia accumulating lipid droplets (LDAM) have been implicated in AD pathogenesis, the mechanistic link between ApoE4 and microglial lipid dysregulation remains elusive. Methods We employed a multi-omics approach, combining snRNA-seq and locus-specific epigenetic analysis, alongside microglia-specific gene manipulation in ApoE-targeted replacement (TR) mice. Primary microglia were challenged with cholesterol to simulate lipid overload conditions. Results In mid-life ApoE4-TR mice, microglia within the dentate gyrus developed pronounced lipid droplet accumulation, concurrent with impaired AÎ² clearance and a pro-inflammatory shift. snRNA-seq unveiled a unique microglial cluster in ApoE4 mice, enriched for lipid-metabolism genes and marked by the pronounced downregulation of the hub gene AsxL1. Mechanistically, ApoE4 attenuated the AsxL1â€“LXRÎ± interaction, leading to reduced H3K4me3 occupancy at promoters of lipid-efflux genes such as Abca1. Crucially, CRISPR-mediated, microglia-specific overexpression of AsxL1 restored H3K4me3 levels, normalized cholesterol efflux, and rescued AÎ² phagocytic deficits in vivo. Conclusions Our findings define an epigenetic pathway whereby ApoE4 drives microglial dysfunction via the AsxL1â€“LXRÎ±â€“H3K4me3 axis, fostering the LDAM phenotype. Enhancing AsxL1 function presents a promising therapeutic avenue for countering ApoE4-mediated pathogenesis in AD.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319246" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE319228 ä½“å†…æŠ‘åˆ¶å­å®«è‚Œç˜¤ä¸­çš„TDO2å¯¼è‡´è‚¿ç˜¤è½¬å½•ç»„å¹¿æ³›æ”¹å˜</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Tsai-Der Chuang ; Abigail Wiseman ; Gabriela Alfaro ; Sayna Pejouhesh Jahromi ; Sepideh Pejouhesh Jahromi ; Daniel Baghdasarian ; Omid KhorramSeries Type : Non-coding RNA profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis study aimed to characterize large and small RNA transcriptomic changes in fibroid xenografts from mice treated with the TDO2 inhibitor 680C91 for two months.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319228" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 24 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>å¤§å‹ç ”ç©¶å‘ç°ï¼Œå­•æœŸæ¥ç§mRNAæ–°å† ç–«è‹—ä¸è‡ªé—­ç—‡ä¹‹é—´æ²¡æœ‰å…³è”</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼švaccine<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers tracked more than 400 toddlers to see whether mRNA COVID-19 vaccination during or just before pregnancy was linked to autism or developmental delays. After detailed assessments of speech, motor skills, behavior, and social development, they found no meaningful differences between vaccinated and unvaccinated groups. Experts say the results provide strong reassurance about vaccine safety in pregnancy.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260215085001.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>äººå·¥æ™ºèƒ½æ­ç¤ºäº†é©±åŠ¨é˜¿å°”èŒ¨æµ·é»˜ç—…çš„éšè—åŸºå› æ§åˆ¶ä¸­å¿ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have created the most detailed maps yet of how genes control one another inside the brains of people with Alzheimerâ€™s disease. Using a powerful new AI-based system called SIGNET, the team uncovered cause-and-effect relationships between genes across six major brain cell types, revealing which genes are truly driving harmful changes. The most dramatic disruptions were found in excitatory neurons, where thousands of genetic interactions appear to be extensively rewired as the disease progresses.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260215084954.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç§‘å­¦å®¶å‘ç°ç¥ç»ä¼šç§¯æä¿ƒè¿›èƒ°è…ºç™Œçš„å‘ç”Ÿå‘å±•ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have uncovered a hidden partnership between pancreatic cancer and the nervous system. Support cells in the pancreas lure nerve fibers, which then release signals that accelerate early cancer growth. This creates a self-sustaining loop that helps tumors take hold. Blocking the nerve activity significantly reduced tumor growth in experiments, suggesting a new treatment strategy.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260211204208.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç§‘å­¦å®¶å‘ç°äº†ä¸€ç§èƒ½è®©ç™Œç»†èƒå¿«é€Ÿé‡ç¼–å…¶DNAçš„é…¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have uncovered the enzyme behind chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers. The enzyme, N4BP2, breaks apart DNA trapped in tiny cellular structures, unleashing a burst of genetic changes that can help tumors rapidly adapt and resist therapy. Blocking the enzyme dramatically reduced this genomic destruction in cancer cells.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260215225546.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>9</td>
</tr>
<tr>
<td>tumor</td>
<td>5</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>5</td>
</tr>
<tr>
<td>immunity</td>
<td>3</td>
</tr>
<tr>
<td>NK cell</td>
<td>3</td>
</tr>
<tr>
<td>metabolic</td>
<td>3</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>2</td>
</tr>
<tr>
<td>scRNA</td>
<td>2</td>
</tr>
<tr>
<td>inflammation</td>
<td>2</td>
</tr>
<tr>
<td>Neuronal</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>sequencing</td>
<td>2</td>
</tr>
<tr>
<td>resistance</td>
<td>2</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>2</td>
</tr>
<tr>
<td>genomics</td>
<td>2</td>
</tr>
<tr>
<td>vaccine</td>
<td>1</td>
</tr>
<tr>
<td>scATAC</td>
<td>1</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>1</td>
</tr>
<tr>
<td>T cell</td>
<td>1</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (24æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309579" target="_blank" rel="noopener noreferrer">GSE309579 æ•´åˆå•ç»†èƒ RNA å’Œ ATAC æµ‹åºæ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤ä¸­å‰‚é‡æ•æ„Ÿã€ç°‡ç‰¹å¼‚æ€§çš„è°ƒæ§åŠ¨æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294799" target="_blank" rel="noopener noreferrer">GSE294799 å¯¹å‘è‚²ä¸­çš„æ–‘é©¬é±¼å’Œäººç±»å†…èƒšå±‚è¿›è¡ŒåŠŸèƒ½åŸºå› ç»„å­¦åˆ†æï¼Œæ­ç¤ºäº†æ§åˆ¶è„Šæ¤åŠ¨ç‰©å™¨å®˜å‘ç”Ÿçš„é«˜åº¦ä¿å®ˆçš„é¡ºå¼è°ƒæ§æ¨¡å—[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294761" target="_blank" rel="noopener noreferrer">GSE294761 å¯¹å‘è‚²ä¸­çš„æ–‘é©¬é±¼å’Œäººç±»å†…èƒšå±‚è¿›è¡ŒåŠŸèƒ½åŸºå› ç»„å­¦åˆ†æï¼Œæ­ç¤ºäº†æ§åˆ¶è„Šæ¤åŠ¨ç‰©å™¨å®˜å‘ç”Ÿçš„é«˜åº¦ä¿å®ˆçš„é¡ºå¼è°ƒæ§æ¨¡å— [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254727" target="_blank" rel="noopener noreferrer">GSE254727 æ‹“æ‰‘ä¿¡æ¯è°ƒæ§å…ƒä»¶é›†åˆåè°ƒç»†èƒèº«ä»½åŸºå› è¡¨è¾¾ç¨‹åº[scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254726" target="_blank" rel="noopener noreferrer">GSE254726 æ‹“æ‰‘ä¿¡æ¯è°ƒæ§å…ƒä»¶é›†åˆåè°ƒç»†èƒèº«ä»½åŸºå› è¡¨è¾¾ç¨‹åº[scATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301801" target="_blank" rel="noopener noreferrer">GSE301801 å¯¹ç»å¯¹ç…§ç»„ã€èƒ†å›ºé†‡è¾…åŠ©æ­£å¸¸æ‰¹æ¬¡ã€æ¯’æ€§æ‰¹æ¬¡å’Œçš®è„‚é…¸å¤„ç†çš„é‡ç”Ÿå‹ C57BL/6 å°é¼ è¿›è¡Œæ‰¹é‡ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298692" target="_blank" rel="noopener noreferrer">GSE298692 ChIP-seq åˆ†æ MM.1S ç»†èƒä¸­çš„ H3K4me3ã€H3K27acã€H3K27me3ã€p-STAT3ã€POU2AF1 å’Œ ELL2</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296093" target="_blank" rel="noopener noreferrer">GSE296093 mRNAç–«è‹—é€šè¿‡éå¸¸è§„é€”å¾„å¯åŠ¨CD8 Tç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162175" target="_blank" rel="noopener noreferrer">GSE162175 ä¸åŒå½¢å¼è¡°è€çš„è½¬å½•ç»„å­¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319394" target="_blank" rel="noopener noreferrer">GSE319394 ä½æ°§æ¡ä»¶ä¸‹ Siniperca chuatsi MFF-1 ç»†èƒçš„ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319347" target="_blank" rel="noopener noreferrer">GSE319347 äººç±» iMGL å’Œ iMGL-è¿åŠ¨ç¥ç»å…ƒå…±åŸ¹å…»ç‰©ä¸ cGAS æŠ‘åˆ¶å‰‚çš„æ‰¹é‡ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319344" target="_blank" rel="noopener noreferrer">GSE319344 è„‘è†œæ·‹å·´ç®¡å†…çš®ç»†èƒçš„ä¸¢å¤±å¯¼è‡´å…·æœ‰æ¸…é™¤åŠŸèƒ½çš„æ–°å‹è¡€ç®¡ç½‘ç»œçš„å½¢æˆã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319333" target="_blank" rel="noopener noreferrer">GSE319333 éå°ç»†èƒè‚ºç™Œ (NSCLC) ä¸­ mtdsRNA æ°´å¹³çš„ç‰¹å¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319316" target="_blank" rel="noopener noreferrer">GSE319316 å±€éƒ¨è´Ÿåé¦ˆå¡‘é€ äº†å‡æ•°åˆ†è£‚DNAæ–­è£‚çš„å…¨åŸºå› ç»„æ¨¡å¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319292" target="_blank" rel="noopener noreferrer">GSE319292 æš´éœ²äºæŒç»­äºšæœ€å¤§å…è®¸æµ“åº¦ (MCL) å’Œè¶…æœ€å¤§å…è®¸æµ“åº¦ (MCL) äºšç ·é…¸é’ å’Œè´«é“€çš„æ–‘é©¬é±¼å¹¼ä½“è½¬å½•ç»„æ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319045" target="_blank" rel="noopener noreferrer">GSE319045 Irx3 é€šè¿‡è°ƒèŠ‚ç‚ç—‡å’Œçº¤ç»´åŒ–é€šè·¯æ”¹å–„å¿ƒè‚Œæ¢—æ­»åå¿ƒè„åŠŸèƒ½éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319035" target="_blank" rel="noopener noreferrer">GSE319035 P21+TREM2+-è¡°è€å·¨å™¬ç»†èƒä¿ƒè¿›ç‚ç—‡è¡°è€å’Œä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…[NAFLD_time_course]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319006" target="_blank" rel="noopener noreferrer">GSE319006 é¶å‘ HDAC å’Œè›‹ç™½è´¨ç¨³æ€ä»¥æ ¹é™¤é™æ­¢ç™Œç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318940" target="_blank" rel="noopener noreferrer">GSE318940 Smarca4 åè°ƒæŸ“è‰²è´¨å¯åŠæ€§å’Œä»£è°¢ç¨‹åºä»¥ç»´æŒé€ è¡€å¹²ç»†èƒåŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318900" target="_blank" rel="noopener noreferrer">GSE318900 åˆ©ç”¨å¤§å‹è¯­è¨€æ¨¡å‹å’Œæ‰©æ•£æ¡†æ¶è§£ç å’Œé‡æ„å¯åŠ¨å­æ¶æ„ï¼šé«˜é€šé‡å¯åŠ¨å­å¼ºåº¦æµ‹åºæºæ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318654" target="_blank" rel="noopener noreferrer">GSE318654 äººç±»è„Šé«“èƒŒè§’å’Œè…¹è§’çš„åˆ†å­å›¾è°±å®šä¹‰äº†ç¥ç»å…ƒç±»å‹çš„æ’åˆ—å’Œç¥ç»èƒ¶è´¨ç»†èƒçš„æ€§åˆ«å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318004" target="_blank" rel="noopener noreferrer">GSE318004 NIK é©±åŠ¨çš„é«“ç³»ç»†èƒ IL-23 äº§ç”Ÿæ˜¯è‡ªèº«å…ç–«æ€§ç‚ç—‡å‘å±•çš„å…³é”®å› ç´  [16S rRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291249" target="_blank" rel="noopener noreferrer">GSE291249 åŒ¹é…çš„å·¦å¿ƒæˆ¿å’Œå³å¿ƒæˆ¿é¢¤åŠ¨äººç±»é˜Ÿåˆ—ä¸­DNAç”²åŸºåŒ–æ°´å¹³çš„è¡¨è§‚åŸºå› ç»„å­¦ç ”ç©¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290099" target="_blank" rel="noopener noreferrer">GSE290099 äººç±»å‰¯æµæ„Ÿç—…æ¯’3å‹æ„ŸæŸ“åäººè‚ºç»„ç»‡çš„å…ç–«ååº”â€”â€”ç»å…¸é€šè·¯å’Œæ²»ç–—</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-16 21:49</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>